Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells

Journal of Neuroscience Research

Volumn 89, Issue 5, 2011, Pages 711-717

  Baron, Nina ^a   Deuster, Oliver ^a   Noelker, Carmen ^a   Stüer, Carsten ^b   Strik, Herwig ^c   Schaller, Carlo ^d   Dodel, Richard ^a   Meyer, Bernhard ^b   Bacher, Michael ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cell death; Cytokine; Glioblastoma; Macrophage inhibitory factor; Neuronal survival

Indexed keywords

CD74 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; MACROPHAGE MIGRATION INHIBITION FACTOR;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GLIOBLASTOMA; GROWTH RATE; HUMAN; HUMAN CELL; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE TARGETING; GLIOBLASTOMA; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; ISOXAZOLES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; RECEPTORS, IMMUNOLOGIC; TUMOR CELLS, CULTURED;

EID: 79952516379     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22595     Document Type: Article

References (38)

1. Arndt U, Wennemuth G, Barth P, Nain M, Al-Abed Y, Meinhardt A, Gemsa D, Bacher M. 2002. Release of macrophage migration inhibitory factor and CXCL8/interleukin-8 from lung epithelial cells rendered necrotic by influenza A virus infection. J Virol 76: 9298-9306.
2. Bacher M, Schrader J, Thompson N, Kuschela K, Gemsa D, Waeber G, Schlegel J. 2003. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol 162: 11-17.
3. Baeza Garcia A, Pierce RJ, Gourbal B, Werkmeister E, Colinet D, Reichhart JM, Dissous C, Coustau C. 2010. Involvement of the cytokine MIF in the snail host immune response to the parasite Schistosoma mansoni. PLoS Pathogen 6: e1001115.
4. Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, Wolfe F, Gregersen PK, Bucala R. 2002. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 3: 170-176.
5. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, Weber C. 2007. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13: 587-596.
6. Calandra T, Bucala R. 1997. Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol 17: 77-88.
7. Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H, Musette S, Darro F, Danguy A, Salmon I, Gabius HJ, Kiss R. 2002. Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 61: 585-596.
8. Case D, Irwin D, Ivester C, Harral J, Morris K, Imamura M, Roedersheimer M, Patterson A, Carr M, Hagen M, Saavedra M, Crossno JJr, Young KA, Dempsey EC, Poirier F, West J, Majka S. 2007. Mice deficient in galectin-1 exhibit attenuated physiological responses to chronic hypoxia-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 292: L154-L164.
9. Donahue TR, Hines OJ. 2009. CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer. World J Surg 33: 710-715.
10. Fingerle-Rowson G, Petrenko O, Metz CN, Forsthuber TG, Mitchell R, Huss R, Moll U, Muller W, Bucala R. 2003. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A 100: 9354-9359.
11. He XX, Chen K, Yang J, Li XY, Gan HY, Liu CY, Coleman TR, Al-Abed Y. 2009. Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med 15: 1-10.
12. Holland EC. 2000. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 97: 6242-6244.
13. Lan HY, Yang N, Nikolic-Paterson DJ, Yu XQ, Mu W, Isbel NM, Metz CN, Bucala R, Atkins RC. 2000. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 57: 499-509.
14. Larsen M, Tazzyman S, Lund EL, Junker N, Lewis CE, Kristjansen PE, Murdoch C. 2008. Hypoxia-induced secretion of macrophage migration-inhibitory factor from MCF-7 breast cancer cells is regulated in a hypoxia-inducible factor-independent manner. Cancer Lett 265: 239-249.
15. Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, Zhao S, Kong C, Richardson D, O'Byrne KJ, Giaccia AJ, Koong AC. 2005. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23: 8932-8941.
16. Legendre H, Decaestecker C, Goris Gbenou M, Nagy N, Hendlisz A, Andre S, Pector JC, Kiss R, Gabius HJ. 2004. Prognostic stratification of Dukes B colon cancer by a neoglycoprotein. Int J Oncol 25: 269-276.
17. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R. 2003. MIF signal transduction initiated by binding to CD74. J Exp Med 197: 1467-1476.
18. Liao H, Bucala R, Mitchell RA. 2003. Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF). J Biol Chem 278: 76-81.
19. Lubetsky JB, Dios A, Han J, Aljabari B, Ruzsicska B, Mitchell R, Lolis E, Al-Abed Y. 2002. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 277: 24976-24982.
20. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. 2002. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 4: 449-460.
21. Meyer-Siegler K, Fattor RA, Hudson PB. 1998. Expression of macrophage migration inhibitory factor in the human prostate. Diagn Mol Pathol 7: 44-50.
22. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. 2006. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 177: 8730-8739.
23. Mitchell RA. 2004. Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 16: 13-19.
24. Mitchell RA, Bucala R. 2000. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol 10: 359-366.
25. Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, Belperio JA, Strieter RM. 2006. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 5: 56-70.
26. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA. 2003. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 100: 13513-13518.
27. Said HM, Hagemann C, Stojic J, Schoemig B, Vince GH, Flentje M, Roosen K, Vordermark D. 2007. GAPDH is not regulated in human glioblastoma under hypoxic conditions. BMC Mol Biol 8: 55-68.
28. Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, Bridger G, Balkwill FR. 2002. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 62: 5930-5938.
29. Shi X, Leng L, Wang T, Wang W, Du X, Li J, McDonald C, Chen Z, Murphy JW, Lolis E, Noble P, Knudson W, Bucala R. 2006. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25: 595-606.
30. Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J. 1999. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 264: 751-758.
31. Singh S, Varney M, Singh RK. 2009. Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res 69: 411-415.
32. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD. 2004. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64: 8604-8612.
33. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, et al. 1995. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270: 27348-27357.
34. Strik HM, Schmidt K, Lingor P, Tonges L, Kugler W, Nitsche M, Rabinovich GA, Bahr M. 2007. Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol Rep 18: 483-488.
35. Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T, Une Y, Todo S. 1998. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med 4: 707-714.
36. 2+ response in rat testicular peritubular cells. Biol Reprod 62: 1632-1639.
37. Yamaoka K, Mishima K, Nagashima Y, Asai A, Sanai Y, Kirino T. 2000. Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J Neurosci Res 59: 722-730.
38. Yoon Y, Liang Z, Zhang X, Choe M, Zhu A, Cho HT, Shin DM, Goodman MM, Chen ZG, Shim H. 2007. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 67: 7518-7524.